CASRAI Dictionary

Tag: consequences of research misconduct

  • Research Integrity Statements: How They Compare

    A research integrity statement is the annual public report a UK university publishes under the Concordat to Support Research Integrity, covering its governance, training and misconduct-handling activity. Depth of disclosure varies sharply: some institutions publish only a principles statement, while others — including the Open University in its 2026 statement — publish allegation tallies and investigation outcomes.

    A research integrity statement is defined by Universities UK’s Concordat as a governing-body-approved annual account of the steps an institution has taken to maintain rigour, transparency, honesty, and accountability in research, alongside a summary of misconduct allegations handled during the reporting year.

    What does the Concordat require in an annual statement?

    The Concordat to Support Research Integrity, coordinated by Universities UK and now overseen by the UK Committee on Research Integrity (UKCORI), requires every signatory to publish an annual statement approved by its governing body. Signatories are transitioning to the refreshed 2025 edition of the Concordat, with full alignment expected by April 2026; until that point, institutions continue reporting against the 2019 edition’s requirements.

    Under both editions, the statement must be publicly accessible on the institution’s website and must include an anonymised account of allegations of research misconduct received and how they were resolved. UKRIO’s self-assessment tooling encourages — but does not mandate — a common template, which is precisely why disclosure quality diverges so widely between institutions.

    • Approval by the university’s governing body (council, senate or board)
    • A narrative on training, culture and support for researchers
    • An anonymised summary of misconduct allegations and outcomes
    • Public web publication, with a copy sent to the Concordat secretariat

    Worked example: the Open University’s 2026 statement

    The Open University’s Research Integrity Statement 2026, approved by OU Council on 3 March 2026, covers the reporting period 1 October 2024 to 30 September 2025. It names Professor Mark Brandon, Pro-Vice-Chancellor for Research and Innovation, as senior lead, with Helen Castley, Senior Manager for Research Governance, as first point of contact.

    The statement discloses three misconduct allegations during the period, none of which proceeded to a formal investigation and none of which were upheld. It also reports the launch of an online research integrity module for postgraduate researchers in autumn 2024, sector-facing open research training, and the university’s signing of the Concordat for Environmental Sustainability of Research. Oversight sits with the Human Research Ethics Committee, an Ethical Research Review Committee, and a newly established Animal Ethics Committee.

    This is a useful baseline because it demonstrates the minimum viable version of Concordat compliance: named accountable officer, dated approval, allegation count, and training update — without case-level detail.

    How does disclosure depth compare across the sector?

    Compliance with the Concordat’s letter does not guarantee comparable transparency. Some institutions publish case-by-case misconduct tables; others confine the public statement to principles and point auditors to an internal report instead.

    Institution Approving body Misconduct data disclosed Training disclosure
    Open University OU Council Allegation count (3), zero formal investigations, none upheld New PGR online integrity module, autumn 2024
    University of Manchester Research Compliance Committee, reporting to Planning and Resources Committee Case-level table (e.g. 7 cases logged in the 2022-23 statement, with faculty, nature and outcome) Mandatory 5-hour course for PGRs, 1-hour course for staff, repeated every 3 years
    University of Cambridge General Board of the Faculties Not published on the public statement page; misconduct reporting sits in a separate Research Integrity Report to Council References Guidelines on Good Research Practice; no published hours or frequency

    The gap is stark: Manchester’s public statement lists individually anonymised case outcomes and quantifies training hours and frequency, while Cambridge’s equivalent page sets out principles and policy links without allegation figures in the same document. The Open University sits between the two, disclosing an allegation count and outcome but not case-level detail.

    For institutions and researchers assessing an organisation’s research misconduct policy or the maturity of its research integrity office, this variance matters more than whether a statement exists at all — a published statement with no allegation data offers limited assurance compared with one that itemises outcomes.

    What should a fully compliant statement include?

    Institutions revising their statement ahead of the April 2026 alignment deadline for the refreshed Concordat should treat the following as a minimum disclosure standard, based on the strongest examples in the sector.

    • Governing-body approval date and named senior accountable officer
    • Defined reporting period (financial or academic year)
    • Anonymised allegation count, broken down by outcome (informal resolution, formal investigation, upheld/not upheld)
    • Description of research integrity training provision, ideally with hours, frequency and audience (staff vs postgraduate researchers)
    • Governance structure — named committee(s) and their reporting line to council or board level
    • Reference to the institution’s research misconduct policy and how allegations are triaged
    • A statement on the consequences of research misconduct applied where allegations are upheld

    Frequently asked questions

    What is an example of a research integrity statement?

    The Open University’s 2026 statement is a working example: approved by OU Council on 3 March 2026, it reports three misconduct allegations, zero formal investigations, and new postgraduate training, alongside named senior accountability under the Concordat.

    What are the five principles of research integrity?

    Universities UK’s Concordat framework, as adapted across UK institutions, defines five core principles: honesty, rigour, transparency and open communication, care and respect for participants and colleagues, and accountability for one’s own research conduct.

    Does a research integrity statement have to report misconduct numbers?

    Yes — the Concordat requires an anonymised summary of misconduct allegations and outcomes in every annual statement. However, no single template is mandatory, so the level of detail — from a bare count to full case tables — varies significantly between institutions.

    Who approves a university’s annual research integrity statement?

    The Concordat requires approval by the institution’s governing body — typically a council, senate or board of governors — often via a delegated committee such as a research compliance or research integrity committee, before public web publication.

    What this means for research administrators

    As institutions align with the refreshed 2025 Concordat ahead of the April 2026 deadline, the sector faces a choice between minimum-viable compliance and genuine transparency. A statement that discloses only principles, with allegation data held back in an internal report, technically satisfies the Concordat’s publication requirement but tells funders, partners and prospective researchers little about how misconduct is actually handled.

    Research administrators drafting or revising a statement should benchmark against Manchester’s case-level disclosure rather than the sector floor, and should treat training hours, frequency and audience as reportable metrics, not narrative colour. Institutions publishing thin statements risk being read — correctly — as less mature on research governance than peers with equivalent misconduct rates but fuller disclosure.

    For research administration teams building out governance documentation more broadly, CASRAI’s research administration resources and research terminology dictionary provide further grounding in the frameworks referenced above.

  • Research Misconduct Policy: Lehigh’s 2026 Update Sets the Pace for Peer Institutions

    A research misconduct policy is the institutional and federal framework that defines fabrication, falsification, and plagiarism (FFP) in research, and sets out how allegations are reported, investigated, and adjudicated. Lehigh University’s new research misconduct policy took effect on 1 January 2026, and it is not an isolated update: dozens of US research universities revised their policies for the same date, all responding to the first substantial rewrite of the federal research misconduct rule in two decades.

    Research misconduct policy in the United States is not institutional discretion. Any university receiving Public Health Service (PHS) funding — the great majority of federally funded research institutions — must maintain a policy satisfying 42 CFR Part 93, administered by the HHS Office of Research Integrity (ORI). When that regulation changes, every covered institution’s policy changes with it. That happened in 2024, and 1 January 2026 is when the consequences arrived on campus.

    What does Lehigh’s new research misconduct policy change?

    Lehigh’s Office of Research Integrity finalised its revised policy on 19 December 2025, in a notice from Naomi E. Coll, Director of Research Policy and Compliance, confirming that the policy would take effect on 1 January 2026. The document sets out how the university assesses, inquires into, and investigates allegations of research misconduct against academic, scientific, and professional staff, students, and contractors, regardless of funding source.

    What distinguishes Lehigh’s process is its provenance rather than its content: the policy was drafted by a faculty working group with one representative from each college, presented to the Faculty Senate in November 2025, and opened to a university-wide online public comment period before finalisation. That sequence — draft, Senate review, public comment, publication — is now a template other institutions are following as they race the same federal deadline.

    What is the federal research misconduct policy institutions must follow?

    The federal research misconduct policy originates with the Office of Science and Technology Policy’s 2000 Federal Policy on Research Misconduct and is codified for PHS-funded research at 42 CFR Part 93. It defines research misconduct as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results — honest error and honest differences of opinion are explicitly excluded.

    A formal finding requires three elements together: a significant departure from accepted practices of the relevant research community, conduct that was intentional, knowing, or reckless, and proof by a preponderance of the evidence. Non-PHS agencies apply parallel rules — the National Science Foundation administers its own version at 45 CFR Part 689 — so multi-funder institutions must reconcile more than one regulatory text in a single policy.

    What changed in the 2024 ORI Final Rule (42 CFR Part 93)?

    ORI published its final rule in the Federal Register on 17 September 2024 — the first substantive revision to the 2005 regulation. The rule became legally effective on 1 January 2025, but institutions only had to apply it to allegations received on or after 1 January 2026, which is why the current wave of policy rewrites is landing now rather than a year ago.

    • Defined intent standard: “Intentionally,” “knowingly,” and “recklessly” — previously undefined terms central to any finding — now carry fixed regulatory definitions.
    • New “institutional record” definition: the rule specifies, for the first time, exactly which documents (inquiry and investigation reports, sequestered evidence indexes, appeal records) must be compiled and preserved.
    • Seven-year retention rule: institutions must secure the institutional record and all sequestered evidence for seven years after the proceeding — or any related HHS proceeding — concludes, whichever is later.
    • Longer inquiry window: the initial inquiry phase is extended from 60 to 90 days, giving Research Integrity Officers more time before deciding whether a full investigation is warranted.

    ORI has confirmed it will not require institutions to submit revised policies until the annual report covering 2025 is filed, due by 30 April 2026 — but the policies themselves, and the procedures behind them, must already be in force for any allegation received from 1 January 2026 onward.

    Which other universities are revising policies for 2026?

    Lehigh is one of a cohort. Institutional policy pages and faculty handbooks show a cluster of revisions timed to the same compliance date, though each institution has followed its own governance path to get there.

    Institution Policy action Date Notes
    Lehigh University New research misconduct policy finalised Effective 1 Jan 2026 Faculty working group, Senate review, public comment
    Columbia University Revised policy approved by University Senate Approved 12 Dec 2025; effective 1 Jan 2026 Realigns definitions with the PHS Final Rule
    Auburn University Policy on Research Misconduct republished 21 Nov 2025 Updated allegation-resolution framework
    Ohio State University Research Misconduct policy revised March 2025 Among the earliest movers ahead of the deadline
    Wayne State University Interim Research Misconduct Policy (26-01) Interim, 2025–26 cycle Document numbering signals the 2026 compliance cycle
    Duke University Misconduct in Research policy (established) Bound to 42 CFR Part 93 / 45 CFR Part 689 Long-cited model policy; must reflect the revised rule by the deadline

    The pattern is consistent: governance bodies — Faculty Senate, University Senate, or equivalent — are being used explicitly to legitimise the revision, not just administrative sign-off. That marks a shift from prior cycles, where research misconduct policy updates were typically handled as compliance housekeeping rather than faculty-governance business.

    Common questions on research misconduct policy

    What are the three forms of research misconduct under US federal policy?

    US federal policy recognises three forms of research misconduct: fabrication (making up data or results), falsification (manipulating materials, equipment, or data so the research record is inaccurate), and plagiarism (appropriating another person’s ideas, processes, results, or words without credit). This “FFP” definition has applied since the 2000 OSTP policy and is unchanged by the 2026 rule.

    What is considered research misconduct in the US?

    Conduct only counts as research misconduct if it is a significant departure from accepted practices of the relevant research community, committed intentionally, knowingly, or recklessly, and proven by a preponderance of the evidence. Honest error, differences of scientific opinion, and most authorship disputes are explicitly excluded from the definition.

    What is 42 CFR Part 93?

    42 CFR Part 93 is the codified federal regulation — the Public Health Service Policies on Research Misconduct — that sets binding rules for how PHS-funded institutions must respond to allegations. Its 2024 revision, effective for allegations from 1 January 2026, is the first major overhaul since 2005 and drives the current round of university policy rewrites.

    What does the federal research misconduct policy cover?

    The federal research misconduct policy covers federally funded research and funding proposals across all fields — including medicine, social sciences, engineering, and statistics — conducted at universities, federal laboratories, and other funded research institutions. It governs the inquiry, investigation, and adjudication phases but does not supersede separate rules on human-subjects protection, animal welfare, or financial conflicts of interest.

    What this means for research administrators

    The consequences of research misconduct under the federal framework range from correction of the research record and letters of reprimand to suspension of funding, debarment from future federal awards, and referral for civil or criminal fraud proceedings. For research administrators, the sharper immediate risk is procedural: if an institution’s inquiry, evidentiary, or retention procedures do not match the 2026 rule, findings made under a defective process are vulnerable on appeal.

    Three takeaways follow. First, Research Integrity Officers should confirm their policy explicitly defines “intentionally,” “knowingly,” and “recklessly” in the regulatory terms now fixed by the final rule, rather than leaving them undefined as most pre-2026 policies did. Second, retention schedules need extending to the mandated seven years and mapped against the newly defined “institutional record.” Third, institutions routing revisions through faculty governance — as Lehigh, Columbia, and Auburn have done — are building a stronger due-process record that may matter if a finding is later contested.

    The compliance clock does not stop at 1 January. ORI’s own review of revised policies, via the annual report covering 2025, falls due on 30 April 2026 — a second checkpoint on which institutions treated this as a genuine revision to research administration practice, and which merely updated a document to survive it.

  • Research Misconduct Examples: Why Reports Hide

    Research misconduct examples are well documented in scholarly literature and case databases, but the investigation reports that actually establish them almost never reach the public. In the UK and the US, institutions overwhelmingly keep findings, evidence and reasoning confidential even after a case closes — a practice that a small number of national bodies elsewhere have abandoned in favour of publishing final rulings.

    Research misconduct is fabrication, falsification, or plagiarism in proposing, performing, reviewing, or reporting research, as defined by the US Office of Research Integrity under 42 CFR Part 93. That definition is narrow by design. It is also, this piece argues, too often the only thing the public is allowed to see — the “what” without the “how we know.”

    What is research misconduct? Definitions and examples

    Fabrication, falsification and plagiarism — FFP — form the internationally recognised core of research misconduct, used by the US Office of Research Integrity (ORI), the UK Research Integrity Office (UKRIO), and the Committee on Publication Ethics (COPE). Fabrication means inventing data or results outright. Falsification means manipulating materials, equipment, images or data so the record misrepresents what actually happened. Plagiarism means presenting someone else’s ideas, data or words as one’s own without attribution.

    Beyond the FFP core, most UK institutional policies and UKRIO’s own guidance extend coverage to related breaches that damage the research record without always meeting the strict fabrication-falsification-plagiarism test:

    • Undisclosed conflicts of interest that could plausibly bias findings or peer review
    • Inappropriate authorship — denying credit to real contributors or granting it to non-contributors, a problem CASRAI’s contributor-role work in CRediT was originally built to address
    • Redundant or “salami-sliced” publication of the same dataset across multiple papers
    • Manipulation of the peer-review process, including fabricated reviewer identities
    • Paper-mill involvement — buying or selling fraudulent manuscripts dressed as original research

    Retraction Watch’s public database tracks the downstream signal of these failures — the retraction itself — but a retraction notice rarely explains what an investigation found. That gap between “a paper was retracted” and “here is the evidence” is the transparency problem this article addresses.

    Why do institutions keep investigation reports confidential?

    UK and US institutions cite broadly consistent reasons for withholding full reports, and some are genuinely legitimate. None justifies blanket non-disclosure once a case is closed and a finding is made.

    • Personnel-record status. Many US institutions classify misconduct files as personnel records, exempting them from public-records requests even at public universities.
    • Whistleblower protection. Confidentiality during an inquiry is defensible — it protects the person who raised the concern from retaliation while facts are established.
    • Reputational risk to the accused. Institutions worry that publishing findings, even redacted ones, will follow a researcher regardless of outcome.
    • Litigation exposure. Legal teams treat investigation reports as liability documents first and research-integrity documents second.
    • No statutory disclosure duty. Unlike the US, where ORI’s federal oversight of Public Health Service-funded research creates a disclosure mechanism, the UK has no national body with investigatory or publication powers.

    The UK’s 2019 Concordat to Support Research Integrity, coordinated by Universities UK, commits signatory institutions to publish an annual statement on how many misconduct allegations they received and investigated. It does not require publication of the underlying reports. This is the crux of the transparency debate: aggregate counts satisfy the letter of accountability while the substance — what was actually found, and how — stays locked in a drawer.

    The US system looks more transparent at first glance because ORI’s Case Summaries register is genuinely public. Read the fine print, though, and the scope narrows sharply: it covers only Public Health Service-funded research, only cases where ORI itself made a finding (institutions handle the great majority internally, without ORI referral), and only researchers currently serving an active administrative sanction — historical entries are removed once the sanction period expires.

    How do more transparent regimes handle disclosure?

    A handful of national systems have made a different bet: that publishing final misconduct decisions, with personal data appropriately redacted, strengthens rather than undermines trust in the research system.

    Jurisdiction Body Investigation outcomes published? Legal basis
    Denmark Danish Committees on Research Misconduct (Nævnet for Videnskabelig Uredelighed) Yes — final decisions published, with case facts, on a rolling basis Danish Act on Research Misconduct (2017)
    Norway National Commission for the Investigation of Research Misconduct (Granskingsutvalget) Yes — decisions published since the commission became operational in 2022 Research Ethics Act (2017, amended)
    Netherlands National Board for Research Integrity (LOWI) Advisory opinions published in anonymised form Netherlands Code of Conduct for Research Integrity
    United States Office of Research Integrity (ORI) Partial — case summaries for PHS-funded, ORI-adjudicated findings only 42 CFR Part 93
    United Kingdom None national; institutions decide individually Rare — annual aggregate statistics only, per the Concordat to Support Research Integrity No statutory research-misconduct framework

    Denmark and Norway share a structural feature the UK and US both lack: a single national committee with statutory authority to investigate and to publish. That centralisation removes the conflict of interest built into the UK and US model, where the institution investigating its own researcher is also the institution deciding whether the findings ever see daylight.

    What does the secrecy cost — and what should change?

    Withholding investigation reports has three concrete costs. First, it prevents the research community from learning the specific mechanics of a case — which is precisely what field-level prevention requires. A retraction notice reading “concerns about data integrity” teaches almost nothing; a published finding detailing exactly which images were duplicated, or which patient records were invented, teaches a field how the fraud was constructed and how it was caught.

    Second, it fuels distrust in the institutions research administrators run. When a case surfaces only through journalism or a whistleblower’s own account — rather than the institution’s — the institution looks like it concealed wrongdoing rather than corrected it, whatever the reality.

    Third, it weakens deterrence. Sanctions that never become public carry a materially smaller reputational cost, changing the incentive calculation for researchers weighing whether to cut corners.

    None of this requires abandoning legitimate protections. A workable model — closer to Denmark’s than the UK’s current default — would:

    1. Publish final findings only, after due process concludes, never mid-investigation
    2. Redact personal data unrelated to the finding itself, while naming the researcher where a finding of misconduct is confirmed and sanctioned, consistent with COPE’s retraction guidelines
    3. Separate the publication decision from the investigating institution, ideally through a national or sector body — the role UKRIO could grow into if given statutory footing
    4. Require research integrity offices to log outcomes in a format compatible with existing registries, including Retraction Watch’s database and journals’ own correction records

    UKRIO’s current remit is advisory, not investigatory — it cannot compel disclosure. Extending it, or creating a UK equivalent of Denmark’s committee, would close the gap between the UK’s stated commitment to research integrity and its practice of keeping the evidence for that commitment confidential.

    Common questions on research misconduct

    What counts as research misconduct?

    Research misconduct is fabrication, falsification, or plagiarism in proposing, performing, reviewing, or reporting research. It excludes honest error and genuine differences of scientific opinion. UK guidance from the UK Research Integrity Office also treats undisclosed conflicts of interest and data manipulation as misconduct.

    What are the three types of research misconduct?

    The three internationally recognised types are fabrication (inventing data), falsification (manipulating materials or altering results), and plagiarism (presenting others’ work as one’s own). This FFP framework, used by ORI and COPE, deliberately excludes honest error and normal scientific disagreement.

    What is considered the most serious form of research misconduct?

    Fabrication is generally treated as the most severe form because it invents an entire dataset or result rather than distorting a real one. In practice, sanctions are often harshest for falsification in clinical or biomedical research, where fabricated or altered findings carry direct patient-safety consequences.

    Investigation-report secrecy is a policy choice, not a technical necessity. Denmark and Norway show that publication and due process are compatible; the UK’s Concordat shows that aggregate transparency, absent case-level disclosure, is not the same thing as accountability. Research administrators and research integrity offices weighing their own disclosure policy now have a working alternative model to point to, not just a set of reasons to say no.

  • Research Misconduct NHS: How Governance Differs from University Policy

    Research misconduct NHS allegations are not resolved as a purely internal university disciplinary matter. Because a designated research sponsor and the Health Research Authority (HRA) hold formal accountability under the UK Policy Framework for Health and Social Care Research, misconduct in NHS-hosted clinical studies routes through trust-level research governance and, for doctors, potential General Medical Council scrutiny — running alongside, not instead of, any university process.

    Research misconduct is behaviour that deliberately or recklessly falls short of the standards expected in the conduct of research, spanning fabrication, falsification, plagiarism, and breaches of the ethical or regulatory approvals a study depends on.

    What Counts as Research Misconduct in NHS-Hosted Research?

    In an NHS setting, research misconduct covers the same core categories recognised across UK research generally, but with an added patient-safety dimension. Proceeding without the ethics approval, HRA Approval, or informed consent a study requires is treated as seriously as fabricating data.

    • Fabrication or falsification of results, including patient consent records
    • Plagiarism of ideas, protocols, or published text
    • Undeclared conflicts of interest affecting clinical decision-making
    • Conducting research without the required ethical or regulatory permissions in place
    • Deviating from an approved protocol without reporting the change

    The UK Research Integrity Office (UKRIO) frames this as behaviour that “deliberately or recklessly” falls short of expected standards — a threshold that separates genuine misconduct from honest error, which most NHS trust policies classify instead as a “questionable research practice” requiring correction rather than disciplinary action.

    Who Investigates? The Sponsor, the HRA and Trust Governance

    The pivotal difference from a university-only inquiry is the statutory concept of the research sponsor. Under the UK Policy Framework for Health and Social Care Research (Health Research Authority and the four UK health departments, first published 2017), the sponsor — usually the NHS trust, a university, or a commercial entity — takes on legal responsibility for confirming a study’s initial and ongoing suitability.

    This changes who is notified and when:

    • The NHS trust’s Research and Development (R&D) office, or the trust’s Director of Research, typically leads the initial assessment of an allegation raised on trust premises
    • Serious breaches of Good Clinical Practice or the approved protocol in a clinical trial must be reported by the sponsor to the HRA (and, for medicines trials, the MHRA) within statutory timeframes — a duty that has no direct equivalent in a purely observational university study
    • The relevant NHS Research Ethics Committee must be informed where the breach affects participant safety or the ethical basis of the study
    • Where fraud is suspected, the NHS Counter Fraud Authority can be engaged in parallel to any research-integrity investigation
    • For registered doctors, nurses, or other regulated professionals, a finding of misconduct can trigger a separate referral to the General Medical Council or equivalent professional regulator, independent of the employer’s own outcome

    UKRIO’s model procedure — the template most university codes of practice are built on — is advisory rather than statutory. NHS research governance, by contrast, sits inside a framework with mandatory reporting duties attached to the sponsor role, which is why an allegation in an NHS-hosted trial can trigger regulatory notifications a university-only investigation would never generate.

    NHS Research Misconduct vs University Procedures: Where They Diverge

    Both systems share the same underlying commitments — the Concordat to Support Research Integrity (Universities UK, 2019) and UKRIO’s guidance inform both — but the accountable parties and mandatory notifications differ sharply.

    Dimension University-led research NHS-hosted clinical research
    Primary framework Concordat to Support Research Integrity (Universities UK, 2019) UK Policy Framework for Health and Social Care Research (HRA, 2017)
    Accountable party The employing institution’s “Named Person” / Responsible Officer The research sponsor, working with the host trust’s R&D office
    Investigating body Institutional panel, often with external academic peers Trust governance process, informed by sponsor obligations to the HRA
    Mandatory external notification Rare — typically only funders or journals if the record needs correcting HRA/MHRA for serious breaches; REC for participant-safety issues; Counter Fraud Authority where fraud is suspected
    Professional regulator exposure Uncommon unless a professional body membership is engaged Possible GMC, NMC or equivalent fitness-to-practise referral for regulated clinicians
    Guiding non-statutory body UKRIO model procedure UKRIO guidance, applied within HRA sponsor obligations

    The practical effect: an NHS-hosted allegation can generate two or more concurrent processes — sponsor/trust governance and, if a professional regulator becomes involved, a fitness-to-practise track — whereas a university-only case usually resolves within a single institutional procedure.

    What Dual-Employment Researchers Need to Know

    Most clinical academics hold a substantive university post alongside an honorary research contract or “letter of access” with an NHS trust, arranged through the NHS Research Passport system. This dual status means an allegation can, in principle, be picked up by either employer’s procedure — or both.

    • Establish early which organisation is the study’s sponsor: sponsor obligations under the UK Policy Framework sit with that entity, not automatically with the employer
    • Expect the university and the NHS trust to agree a lead institution for the investigation, informed by UKRIO’s guidance on cross-institutional cooperation, with the second body kept informed rather than running a parallel duplicate inquiry
    • Understand that an honorary contract does not exempt a researcher from either institution’s disciplinary powers — sanctions (suspension of research privileges, restriction of clinical duties, dismissal) can be applied independently by each party
    • Keep records of ethical approvals, protocol versions, and consent documentation accessible to both employers, since a trust R&D office and a university research office may request the same evidence separately

    Research administrators supporting joint appointments should confirm, before a study opens, which institution’s misconduct procedure will apply if a concern is raised — this sits alongside the wider governance responsibilities covered under research administration frameworks.

    Frequently Asked Questions

    What is an example of misconduct in the NHS?

    In an NHS research context, a documented example is proceeding with a clinical trial without valid ethics approval or falsifying patient consent records. Both breach the UK Policy Framework for Health and Social Care Research and trigger sponsor reporting duties to the Health Research Authority, independent of any wider workplace conduct issue.

    What are the three types of research misconduct?

    The three most widely recognised categories are fabrication (inventing data or results), falsification (manipulating data, materials, or processes to misrepresent findings), and plagiarism (using others’ work or ideas without acknowledgement). UK bodies including UKRIO also recognise a broader “questionable research practices” category for less severe lapses.

    What is considered the most serious form of research misconduct?

    Fabrication of results or consent data is generally treated as the most serious category, because it directly corrupts the evidence base and, in clinical research, can endanger patient safety. In NHS-hosted studies, fabrication findings typically prompt both sponsor notification to the HRA and professional regulator referral for the individual involved.

    What is a sackable offence in NHS?

    A confirmed finding of fabrication or falsification in NHS-hosted research is normally treated as gross misconduct and can constitute a sackable offence under trust disciplinary policy. For registered clinicians, the same finding can additionally trigger a General Medical Council fitness-to-practise referral, separate from the employer’s own decision.

    The structural distinction matters beyond individual cases. As more clinical trials run through joint university–NHS sponsorship arrangements, institutions that treat research governance as a single, unified track — rather than mapping sponsor, trust, and employer obligations separately — risk missing mandatory notifications the UK Policy Framework requires. Clear, pre-agreed lead-institution protocols for dual-employment researchers remain the most effective safeguard.

  • Retraction in Academic Publishing: A Terminology Guide for Editors and Research Offices

    Editors, research-integrity officers and authors routinely use “retraction”, “correction”, “expression of concern” and “redaction” as if they were interchangeable. They are not. Retraction in academic publishing is a formal, permanent withdrawal of a paper’s standing, reserved for findings that can no longer be trusted — a different remedy, with a different evidence threshold, from a correction, an expression of concern, or a redaction. Conflating the terms slows investigations and can misstate a case’s severity to funders, tenure committees, and the public record.

    The four publishing remedies at a glance

    The Committee on Publication Ethics (COPE), whose retraction guidelines were updated to version 3 in August 2025, and the International Committee of Medical Journal Editors (ICMJE) both treat these as distinct editorial tools, not synonyms. The table below sets out the working distinctions research offices and editorial staff need.

    Remedy What it means Typical trigger Who issues it Effect on the original article
    Retraction Formal, permanent withdrawal from the reliable literature Fabrication, falsification, plagiarism, unethical research, compromised peer review Editor, sometimes jointly with the publisher Article stays online, clearly watermarked “RETRACTED”
    Correction (corrigendum/erratum) Fixes a specific, non-fatal error Author error (corrigendum) or production error (erratum) Authors (corrigendum) or journal (erratum) Article stands; correction notice is linked to it
    Expression of concern Interim public notice pending an unresolved inquiry Inconclusive evidence or an ongoing institutional investigation Editor Article stands, flagged as under review
    Redaction Removal or masking of specific sensitive content only Legal, privacy, or confidentiality requirement (e.g. identifiable patient data) Publisher, usually on legal or data-protection advice Only the redacted portion is withheld; the rest of the record stands

    Retraction: when findings cannot be trusted

    Per COPE’s 2025 retraction guidelines, “the purpose of retraction is to correct the literature and ensure its integrity, not to punish the authors.” A retraction disavows the paper’s conclusions; it does not usually remove the text itself, which stays accessible but permanently marked as unreliable.

    COPE and ICMJE both point to a similar set of grounds for retraction:

    • Unreliable findings — from honest error (miscalculation, flawed methodology) or from misconduct (fabricated or falsified data)
    • Plagiarism — appropriating another party’s words, data, or ideas without credit
    • Redundant or duplicate publication — the same findings published elsewhere without cross-reference or permission
    • Unethical research — studies that breached human- or animal-subject ethics requirements
    • Compromised peer review or undisclosed conflicts of interest that could have biased the editorial decision

    A retraction can be initiated by authors, editors, or the publisher, but COPE is explicit that the editor holds final decision authority, consistent with editorial independence — the publisher’s role is to support the investigation and help issue the notice, not to make the call.

    Correction, corrigendum and erratum: fixing the record without withdrawing it

    A correction is the appropriate remedy when an error is real but does not undermine the paper’s overall conclusions — a mislabelled figure, an incorrect affiliation, a transposed digit in a table. Two related terms are often used loosely but have a real distinction:

    • Corrigendum — a correction of an error introduced by the authors themselves
    • Erratum — a correction of an error introduced by the journal during production

    Both are published as a linked notice attached to the original article, which otherwise remains part of the reliable record. A correction is not a lesser form of retraction — it is a separate remedy for a separate class of problem, and treating minor corrections as reputational events discourages the self-correction that COPE and ICMJE actively encourage.

    Expression of concern: the interim signal

    An expression of concern (EOC) is not a verdict. COPE’s guidance describes it as the appropriate step when an editor is uncertain about a publication’s reliability because of insufficient information, delays in institutional response, or an investigation that will not conclude quickly. Rather than wait — and risk the paper being cited or acted on in the meantime — the editor publishes a notice flagging the concern while the inquiry continues.

    An EOC typically resolves in one of three ways: retraction, correction, or a formal confirmation that the concerns did not hold up. Editorial and research-integrity teams should track EOCs as open cases, not closed ones, and revisit them on a defined schedule rather than leaving them unresolved indefinitely.

    Redaction vs retraction: a different kind of removal

    This is where terminology confusion is most common — and most consequential. Redaction is not a recognised category within the COPE/ICMJE retraction-correction-EOC taxonomy. It is a records-management and legal term for the selective removal or masking of specific sensitive content — identifiable patient information, confidential commercial data, material under a court order — while the rest of the document remains intact and in force.

    Retraction, by contrast, withdraws the paper’s standing as a whole. A journal might redact one identifying detail from a case report to comply with data-protection law without touching the paper’s scientific conclusions; that is not equivalent to, and should never be reported internally as, a retraction. Research offices logging cases for funder reporting should keep these as separate fields — collapsing them into one “removed” category misrepresents both the scale and the cause of the action.

    Answer-first questions editors ask

    What does it mean if a publication is retracted?

    A retracted publication has been formally withdrawn from the reliable scholarly record by its editor, usually because of unreliable data, misconduct, or a serious ethical breach. The article typically remains online, watermarked “RETRACTED”, so the record stays transparent rather than being erased.

    What is the purpose of retractions in academic publishing?

    Retraction exists to correct the literature and protect its integrity, not to punish authors, per COPE’s own guidelines. It warns future readers, citing authors, and clinicians not to rely on the paper’s findings or conclusions, limiting downstream harm from erroneous or fraudulent results.

    Do retracted studies still get cited?

    Yes — research tracked via PubMed Central and the Retraction Watch database shows retracted papers continue to be cited after retraction, sometimes for years, often because citing authors are unaware of the notice. This is why prompt, linked, machine-readable retraction notices matter so much for discovery.

    Can a retracted paper be published again?

    A substantially revised version can sometimes be resubmitted if the authors have genuinely corrected the underlying problem, but this must be done transparently, with the editor informed of the paper’s history. It is never appropriate to resubmit a corrected version without disclosing the prior retraction.

    What this means for editors and research offices

    For journals, precise terminology is a workflow issue as much as an editorial-ethics one: COPE’s flowcharts, ICMJE’s recommendations, and most editorial-management systems expect cases to be tagged with the correct remedy from the outset, because that tag drives downstream indexing signals sent to CrossRef, PubMed, and DOI registries.

    For research offices, the stakes are similar. Case files, funder disclosures, and research-administration compliance reports should mirror the same four-way distinction rather than defaulting to informal language like “the paper was pulled.” Where a case originates in a dispute over who contributed what to a flawed paper, structured contributor statements — the kind increasingly requested under authorship policies — can help institutions establish individual accountability before deciding whether the remedy is a correction or a full retraction. Internal glossaries and training materials can also be cross-referenced against a maintained dictionary of research-administration terminology rather than drafted informally office by office.

    The rise of paper-mill detection tools has also pushed COPE to add explicit guidance on batch retractions — cases where dozens or hundreds of articles from the same source are retracted together for the same systemic reason. That volume makes definitional discipline more urgent: a research office tracking hundreds of cases needs the four categories kept clean to report accurately to funders and institutional leadership.

    Looking ahead

    As journals face more paper-mill-driven batch retractions and more AI-assisted-writing disclosures, the boundary between “correction” and “retraction” will keep being tested in ways COPE’s earlier guidelines did not originally anticipate. Editors and research offices that maintain a precise, shared vocabulary — retraction, correction, expression of concern, and redaction as four distinct tools rather than one blurred category — will be better placed to report consistently, protect the record, and respond quickly when the next systemic case emerges.

  • Becoming a Research Integrity Officer: Role, Remit and Career Pathway

    As UK universities and research institutes face growing scrutiny over reproducibility, authorship disputes and data fabrication cases, the research integrity officer has moved from a part-time academic add-on to a defined, increasingly professionalised post within research governance teams. For research administrators considering a move into this specialism — or institutions building the role for the first time — the practical questions are consistent: what does the job actually involve, how is it distinct from a research ethics post, and what does it pay.

    What Does a Research Integrity Officer Do?

    A research integrity officer (RIO) is the named individual — sometimes a dedicated post, sometimes a senior academic holding the title alongside other duties — responsible for an institution’s response to concerns about the conduct of research. The remit sits within research governance rather than within a single department, because misconduct allegations can touch grants, publications, supervision and institutional reputation simultaneously.

    Core duties typically include:

    • Managing misconduct allegations — receiving, triaging and, where warranted, formally investigating concerns about fabrication, falsification, plagiarism or other breaches of good research practice.
    • Policy ownership — drafting and maintaining the institution’s research integrity policy and investigation procedures, aligned to the Concordat to Support Research Integrity.
    • Advice and training — briefing researchers, supervisors and postgraduates on responsible research conduct, data management and authorship practice.
    • Horizon-scanning — tracking changes to funder and regulatory requirements and briefing senior leadership on their implications.
    • External liaison — reporting to funders, and in serious cases coordinating with bodies such as UKRIO or equivalent national offices, when an institution’s own procedures require external assurance.

    Unlike a compliance officer, the RIO role is deliberately dual-facing: part investigator, part educator. That combination is what distinguishes it from adjacent research-governance posts and is a recurring theme across UK job descriptions for the role.

    Common Questions About the Role

    What does a research integrity officer do?

    A research integrity officer manages an institution’s response to alleged research misconduct, advises staff and students on good research practice, develops integrity policy, delivers training, and liaises with funders and oversight bodies such as UKRIO or, in the US, the Office of Research Integrity.

    What are the core principles of research integrity?

    In the UK, the Concordat to Support Research Integrity sets out five commitments: honesty, rigour, transparency and open communication, care and respect, and accountability. These underpin institutional policy and RIO casework across the sector.

    What is an integrity officer?

    An integrity officer is a role, not exclusive to research, focused on upholding ethical standards and investigating breaches of conduct within an organisation. In a research setting this narrows to allegations of fabrication, falsification and plagiarism, plus wider good-practice oversight.

    What is the UK Research Integrity Office?

    The UK Research Integrity Office (UKRIO) is an independent charity, not a regulator, that provides confidential advice, training and a Code of Practice for Research to institutions and individuals — it does not employ institutional research integrity officers directly.

    Research Integrity Officer vs Research Ethics Officer

    The two titles are frequently confused, including in job adverts, but the remits are distinct and often sit in separate reporting lines within the same institution.

    Dimension Research Integrity Officer Research Ethics Officer
    Primary focus Conduct of research after it has started — misconduct allegations, data integrity, authorship disputes Approval of research before it starts — participant welfare, consent, risk to human/animal subjects
    Typical trigger A complaint, whistleblower report or funder query about existing work A new study protocol requiring ethical review before data collection
    Governing framework Concordat to Support Research Integrity; institutional misconduct procedure Institutional Research Ethics Committee (REC) terms of reference; Declaration of Helsinki-derived norms
    Reporting relationship Often reports to the Pro-Vice-Chancellor for Research or Registrar Often reports to, or chairs, a Research Ethics Committee
    External counterpart UKRIO (UK); Office of Research Integrity (US); ENRIO members (EU) National/institutional research ethics committee networks

    In practice the two functions overlap at the edges — an ethics breach discovered mid-study can escalate into a misconduct investigation — which is why some smaller institutions combine both under a single research governance lead. Larger research-intensive universities more often separate them into distinct posts.

    Career Pathway and UK Salary Bands

    There is no single accredited qualification that leads directly into the role, which mirrors the position taken by UKRIO and by sector guidance more broadly. Instead, institutions typically recruit against a combination of research background, governance experience and demonstrable case-handling skill. Common entry routes include:

    1. Academic-to-governance move — a PhD-holding researcher moves into research office or governance work, often via a research ethics committee or integrity champion role first.
    2. Research administration progression — an experienced research administrator or grants manager takes on integrity casework as their portfolio grows, then formalises it into a dedicated post.
    3. Legal, compliance or audit background — professionals with investigation, HR-casework or regulatory experience move into research settings, particularly at larger institutions with dedicated Research Governance or Research Integrity offices.
    4. Direct RIO appointment — increasingly common at research-intensive universities, advertised as a standalone senior professional-services post rather than an academic add-on.

    Salary bands vary by institution, grading framework (most UK universities use HERA-derived single pay spines) and whether the post is a stand-alone specialism or combined with wider research governance duties. As an indicative guide only:

    Post level Typical UK context Indicative salary band
    Research Integrity Adviser / Officer Mid-career professional-services role, single institution Broadly £35,000–£48,000
    Senior Research Integrity/Governance Officer Case-handling lead, policy ownership Broadly £48,000–£60,000
    Head of Research Integrity/Governance Strategic lead, reports to senior leadership, larger research-intensive institution Broadly £60,000+

    These bands are indicative only — always verify against the specific institution’s published grading and current job advert, since London weighting, faculty co-funding and combined governance/ethics portfolios all shift the figure materially.

    What This Means for Institutions

    As funders and publishers tighten expectations around data availability, image integrity checks and authorship accuracy, institutions without a clearly defined RIO post risk slower, less consistent responses to misconduct concerns — a reputational and compliance exposure that research administration leadership increasingly treats as a governance priority rather than an academic-freedom afterthought. Clear separation from the research ethics function, rather than folding both into one overstretched role, tends to produce faster case turnaround and clearer audit trails for funders such as UKRI.

    Authorship disputes in particular sit at the intersection of both functions and are a growing share of RIO caseload as contributor-role expectations become more explicit; institutions benefit from RIOs who understand current authorship norms as well as misconduct procedure.

    Outlook: A Professionalising Field

    Expect continued formalisation of the RIO role through the later 2020s: more standalone advertised posts, clearer competency frameworks referencing the Concordat to Support Research Integrity, and closer alignment between UK institutional practice and European counterparts coordinated through ENRIO. For research administrators and early-career researchers weighing a move into this specialism, the practical route in remains consistent — build governance, casework and policy experience, engage with UKRIO’s training resources, and be explicit in applications about the distinction between integrity and ethics remits, since institutions are increasingly hiring for one or the other rather than a blended generalist post.

  • Famous Cases of Research Misconduct: Procedural Lessons from Stanford and Harvard

    The most famous cases of research misconduct rarely turn on a single fabricated data point. They turn on how an institution responds once a concern surfaces: who is notified, how quickly a panel is convened, what gets published, and what stays confidential. The 2023 resignation of Stanford University’s president, Marc Tessier-Lavigne, and the parallel investigation into Harvard Business School professor Francesca Gino gave research integrity offices two live, closely watched case studies in exactly that process, separate from the underlying scientific disputes.

    Both cases ran on strikingly different tracks: one via an independent trustee-commissioned panel responding to press and PubPeer scrutiny, the other via a confidential internal Research Integrity Officer inquiry triggered by a data-forensics blog. Comparing them, and three earlier landmark cases, surfaces recurring procedural failure points that any research administration office can audit against its own protocols.

    Why these cases matter to research integrity offices

    Research misconduct investigations are procedurally distinct from routine peer-review corrections. Under the US Office of Research Integrity’s (ORI) definitions, misconduct comprises fabrication, falsification, and plagiarism — not honest error, and not scientific disagreement. Getting that distinction right, early, determines whether a case is handled as a correction, a retraction, or a formal misconduct finding with employment consequences.

    The Stanford and Harvard cases are instructive precisely because they show two institutions applying that distinction under public pressure, at speed, with reputational stakes attached to the outcome.

    The Stanford presidency: oversight, not fabrication

    Marc Tessier-Lavigne resigned as Stanford’s president in July 2023 after a Special Committee of the Board of Trustees, assisted by an outside scientific panel, reviewed allegations first amplified by student newspaper reporting and image-integrity comments on PubPeer. The panel’s report did not find that Tessier-Lavigne personally falsified data. It found manipulated images and unreliable data across several papers from labs he had run at different institutions, and — the procedurally decisive finding — that he had failed to act “decisively and forthrightly” to correct the record once concerns were raised over several years.

    • Investigation body: an independent Special Committee plus an outside scientific review panel, not the university’s standing research-integrity office, reflecting the conflict of interest inherent in investigating a sitting president.
    • Trigger: student journalism and public PubPeer commentary, not an internal whistle-blower report.
    • Outcome: resignation as president; five papers slated for retraction or correction; Tessier-Lavigne retained his tenured faculty position.

    For research administrators, the lesson is less about the science and more about escalation pathways: when the subject of a complaint holds institutional authority, governance structures must route the inquiry outside the normal chain of command from the outset.

    Francesca Gino at Harvard: whistle-blowers, investigation, litigation

    Harvard’s case followed a different route. In 2021, the behavioural-science bloggers behind Data Colada flagged anomalies in four of Francesca Gino’s papers to Harvard directly. The university’s Research Integrity Officer opened a confidential inquiry that produced a roughly 1,200-page report, concluding Gino had “committed research misconduct intentionally, knowingly, or recklessly.” She was placed on unpaid administrative leave in June 2023, shortly before Data Colada published its findings publicly.

    Gino has denied the findings and, in August 2023, filed a $25 million lawsuit against Harvard, its dean, and the three Data Colada researchers, alleging defamation and gender discrimination. A federal judge dismissed the claims against the Data Colada authors and several claims against Harvard in September 2024, though parts of the litigation continue.

    • Investigation body: Harvard’s internal Research Integrity Officer process, kept confidential during the inquiry itself.
    • Trigger: an external, methodologically detailed whistle-blower report from named researchers running a public blog.
    • Outcome: administrative leave, retractions, and multi-year litigation that has kept the case — and the institution’s internal report — in the public record long after the initial finding.

    The litigation risk here is the procedural lesson generic “list of cases” coverage tends to skip: a confidential process does not stay confidential once litigation compels disclosure, and institutions should draft misconduct reports with that eventual exposure in mind.

    Five cases compared: triggers, investigators, outcomes

    Set alongside three earlier landmark cases, the Stanford and Harvard investigations show a consistent pattern: the trigger for an inquiry is now more often external scrutiny — journalists, forensic bloggers, or peer-commentary platforms — than an internal audit.

    Case Institution What triggered the inquiry Investigating body Outcome
    Marc Tessier-Lavigne Stanford University Student journalism, PubPeer comments Independent trustee-commissioned panel Resigned as president, July 2023; retractions pending
    Francesca Gino Harvard Business School Data Colada whistle-blower report (2021) Harvard Research Integrity Officer Unpaid leave, June 2023; ongoing litigation
    Diederik Stapel Tilburg University Junior researchers raised concerns Levelt, Noort and Drenth Committees Resigned 2011; roughly 55 papers retracted
    Jan Hendrik Schön Bell Laboratories Peers noticed duplicated data across papers Internal Bell Labs investigation committee Dismissed 2002; PhD revoked 2004
    Hwang Woo-suk Seoul National University Investigative journalism and insider tips University investigation panel Dismissed 2006; later convicted on related charges

    Common questions about research misconduct cases

    What are some examples of research misconduct?

    Classic examples include fabricating data that was never collected, as in the Stapel case; falsifying results to match a hypothesis, as alleged in the Gino papers; and image manipulation across multiple publications, the pattern identified in the Tessier-Lavigne review. Plagiarism of text or ideas is the third recognised category under most institutional and federal definitions.

    What is considered the most serious form of research misconduct?

    Fabrication is generally treated as the most serious category, because it invents phenomena outright rather than distorting real data. Falsification is a close second, since it corrupts genuine findings. Both differ fundamentally from honest error or a good-faith methodological dispute, which do not meet the threshold for a misconduct finding.

    What are some examples of academic misconduct?

    Academic misconduct is a broader category than research misconduct, and includes duplicate publication, undisclosed conflicts of interest, ghost or guest authorship, and failure to secure ethics approval, alongside the fabrication, falsification, and plagiarism that define research misconduct specifically under ORI and most university policies.

    What research offices should take away

    Five recurring procedural patterns emerge across these cases:

    1. Escalation independence. When a complaint touches senior leadership, route the inquiry to a body outside the normal reporting line — Stanford’s use of an independent trustee committee is the model.
    2. External triggers now dominate. Four of the five cases here were surfaced by outsiders — journalists, junior researchers, or forensic bloggers — not internal audit. Offices should treat external tip lines as a primary detection channel, not a fallback.
    3. Draft for eventual disclosure. Gino’s litigation shows that confidential reports can become public exhibits; findings should be evidenced and worded accordingly.
    4. Corresponding-author accountability matters. Several of these cases turned on unclear responsibility for data supplied by co-authors or lab members — a governance gap that clearer authorship and contributorship practices help close, including explicit use of contributor-role frameworks for accountability mapping.
    5. Timelines are long. None of these cases resolved in under a year; Gino’s litigation is still active more than three years after Data Colada’s initial report to Harvard. Offices should plan communications and interim-measures policy for multi-year timelines, not single-semester ones.

    Institutions building or revising misconduct policy can benchmark their escalation, notification, and disclosure procedures against these patterns through established research administration frameworks, and can consult standard definitions of the terms involved via CASRAI’s open research vocabulary.

    Looking ahead: building resilient response processes

    The Stanford and Harvard cases will keep generating secondary coverage — retractions, court filings, follow-on reporting — for years, which is itself a lesson: a misconduct case is not closed when a leave notice or resignation is announced. Research integrity offices that treat these as multi-year, cross-functional processes, spanning HR, legal, communications, and the research office itself, are better positioned than those that treat a finding as the end state.

    As data-forensics blogs, image-integrity tools, and post-publication review platforms proliferate, external detection will keep outpacing internal audit capacity. The institutions that fare best will be the ones with pre-agreed escalation pathways, disclosure-ready documentation standards, and clear contributor-accountability frameworks already in place before the next high-profile case breaks.

  • Research Misconduct and the Guarantor Author: Why Corresponding Authors Carry More Risk

    The Office of Research Integrity research misconduct process — and its UK counterpart, the UK Research Integrity Office (UKRIO) — was not designed around a single author byline. It was designed around named investigators who can be held individually accountable. That is precisely why the guarantor and corresponding author roles matter so much more than most authorship guidance admits. When an allegation of fabrication, falsification, or plagiarism (FFP) lands on an institution’s desk, it does not spread evenly across the byline. It lands hardest on whoever agreed to answer for the work as a whole.

    Coverage of author-contribution statements — CRediT tags, ICMJE criteria, “who did what” disclosures — tends to treat authorship as a credit-allocation problem. This piece takes a narrower, more consequential angle: the guarantor and corresponding author roles are accountability-allocation mechanisms, and they carry meaningfully different legal and institutional exposure than ordinary co-authorship.

    Guarantor vs corresponding author: two roles, often confused

    The two roles are frequently collapsed into one person, but they are not the same function.

    • Corresponding author — per ICMJE, “the one individual who takes primary responsibility for communication with the journal during the manuscript submission, peer-review, and publication process,” including ethics approvals, disclosures, and post-publication queries.
    • Guarantor — a role some journals (notably BMJ and Cell Press titles) formalise separately, describing the guarantor as the person who “takes responsibility for the integrity of the work as a whole, from inception to published article.”

    Cell Press editors proposed uncoupling the two designations explicitly, noting that as author lists grow — averaging roughly 5.25 authors per paper by 2012, nearly double the 1980 figure — no single contributor can plausibly vouch for every dataset. A named guarantor, distinct from whoever merely handles journal correspondence, was their proposed fix. Many journals still have not adopted the split, which is exactly why disputes over “who was actually accountable” recur when misconduct is alleged.

    Why the distinction matters once misconduct is alleged

    ICMJE’s fourth authorship criterion requires “agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.” Every listed author technically signs up to this. In practice, investigators treat it unevenly.

    In the United States, the HHS Office of Research Integrity defines research misconduct under 42 CFR Part 93 as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting results — explicitly excluding honest error and genuine differences of opinion. ORI does not conduct most investigations itself; federally funded institutions do, under their own procedures, with ORI providing oversight and the power to impose findings such as debarment from federal funding.

    Three factors sharpen exposure for guarantors and corresponding authors specifically:

    1. Presumed oversight duty. A corresponding or guarantor author who failed to verify underlying data can be found to have acted recklessly, even absent direct knowledge of fabrication — a lower bar than intentional deception.
    2. Grant and funder exposure. Where federally or publicly funded research is involved, false statements in grant applications or resulting publications can trigger civil liability distinct from the institutional misconduct finding itself.
    3. Correction and retraction duties fall to them. Journals route retraction and correction processes through the corresponding author, making that person the operational face of any remediation — regardless of who actually generated the disputed data.

    Answer-first: the questions researchers actually ask

    What is the difference between a guarantor and a corresponding author?

    The guarantor takes responsibility for the integrity of the work as a whole, from inception to publication, including verifying that the data are sound. The corresponding author is the primary contact point for the journal during submission, peer review and after publication. Some journals require these to be the same person; others, including BMJ, allow separate designations.

    What are the responsibilities of a corresponding author?

    A corresponding author ensures ethics approvals, disclosures and authorship details are correctly reported to the journal, remains available to respond to editorial queries during review, and stays reachable after publication to address data requests or critiques. ICMJE recommends journals still copy all listed authors on correspondence, not only this individual.

    Is corresponding author a big deal?

    Yes — despite sometimes being treated as a routine administrative label, it carries real accountability weight. The corresponding author is not automatically the most senior researcher, but investigators, journals and funders typically direct misconduct queries, correction requests and retraction proceedings to this person first, well before other co-authors are contacted.

    How ORI and UKRIO assess culpability differently

    The US and UK systems share the same core definition of misconduct (fabrication, falsification, plagiarism) but differ sharply in enforcement architecture — a distinction rarely made explicit in guidance aimed at authors.

    Feature United States (ORI / HHS) United Kingdom (UKRIO / UKCORI)
    Statutory basis 42 CFR Part 93 (federal regulation) No single statutory body; sector-agreed Concordat to Support Research Integrity
    Who investigates The funded institution, with ORI oversight of PHS-funded research The employing institution, with UKRIO offering advisory support on request
    Sanction power ORI can debar individuals from federal funding No central debarment power; sanctions are institutional (dismissal, retraction referral)
    Public reporting ORI publishes case summaries and administrative actions UKCORI publishes an annual sector-wide statement, not individual case findings
    Author-role focus Investigations increasingly examine individual contribution and supervisory role Institutional codes (e.g., UKRIO’s Code of Practice for Research) stress joint and individual responsibility

    Neither system has a formal legal category called “guarantor.” Both, however, are moving toward differentiated rather than collective culpability — meaning the person who signed as corresponding author or accepted the guarantor role is increasingly the first, not the last, name investigators examine.

    Implications for institutions, journals and PIs

    For research administrators and institutional leaders, three practical consequences follow:

    • Authorship agreements signed before submission should record, in writing, who is guarantor and who is corresponding author — they need not be the same person.
    • Data-verification procedures should be documented contemporaneously, since “did the guarantor take reasonable steps to verify the data” is now a live question in culpability assessments, not an afterthought.
    • Early-career researchers pressured into corresponding-author roles as a “credit” gesture should understand the accountability that travels with the title, not just the citation visibility.

    None of this replaces institutional legal advice once an allegation is formally lodged — but it does mean the accountability conversation should happen at submission, not after a correction letter arrives.

    Where contribution taxonomies fit — and where they don’t

    It is tempting to assume that a granular contribution taxonomy resolves the guarantor question. It does not, by design. CASRAI originated the CRediT contributor role taxonomy in 2014, and the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022. CRediT records what each contributor did — conceptualisation, data curation, formal analysis, and so on — but it deliberately does not assign overall accountability for the integrity of the finished article. That is a separate governance question, answered by journal policy and institutional procedure, not by the taxonomy.

    Understanding the distinct CRediT contributor roles alongside the broader authorship criteria frameworks helps research offices see the gap clearly: a taxonomy can show who curated the data, but only a named guarantor or corresponding author can be held to account for whether that data was verified before publication. Research administration teams building institutional policy around the CRediT taxonomy should treat guarantor designation as a distinct, additional step — not something the taxonomy already covers.

    As funders and journals continue tightening data-verification and retraction workflows, the guarantor and corresponding author roles are likely to become more formally defined, not less. Institutions that document these roles clearly at submission — rather than defaulting to “whoever emailed the journal” — will be better placed when an allegation, however rare, actually arrives.

  • Research Misconduct Penalties: Vietnam’s New Tiered System

    Vietnam has become the latest country to formalise research misconduct penalties into a graduated, rules-based system. A 25 May 2026 directive from the Ministry of Science and Technology, first reported by Retraction Watch, moves the country from voluntary integrity principles toward enforceable sanctions — written warnings, public apologies, funding claw-backs and indefinite bans — scaled to the severity of the offence. For institutions and funders elsewhere weighing graduated sanctions frameworks, Vietnam’s approach is a live case study in proportionate enforcement.

    Vietnam’s new framework: what the Ministry announced

    The guidance requires every science and technology organisation in Vietnam to adopt formal rules against research misconduct and to follow a defined process for investigating and sanctioning violations. Before the directive, integrity expectations existed mainly as general principles encouraged on a voluntary basis, without a consistent enforcement mechanism across institutions.

    The framework names four categories as the most serious violations:

    • Fabricating data
    • Plagiarising others’ work
    • Concealing conflicts of interest
    • Acts that distort the true nature of the research

    Notably, the guidance also addresses generative-AI misuse directly — creating fake data or images, or citing unverified AI-generated material as a reference are both classed as violations. Researchers are additionally required to run plagiarism checks before submission, retain raw data and research logs, and disclose funding sources, conflicts of interest and any AI use. Confirmed violations must be logged on Vietnam’s National Digital Platform for Science, Technology and Innovation Management, giving the sanctions a permanent, searchable public record.

    A tiered system: how the penalties scale with severity

    Rather than a single blanket punishment, the framework sets out a ladder of responses, so that a first, low-level infraction is treated differently from deliberate fabrication. This proportionality principle is common to most mature integrity systems, but Vietnam’s version is unusually explicit about which penalty attaches to which tier.

    Severity tier Example conduct Typical sanction
    Lower tier Procedural lapses, inadequate disclosure Written warning, mandatory training
    Mid tier Undisclosed conflicts of interest, authorship disputes Correction/retraction request, public apology, role suspension
    Upper tier Fabrication, falsification, plagiarism, concealed AI misuse Return of research funding, permanent or indefinite project ban

    The Ministry’s move follows years of pressure from documented cases. Retraction Watch’s database records 251 retractions carrying a Vietnamese institutional affiliation, with Ton Duc Thang University and Duy Tan University accounting for the largest share. Investigative reporting by the newspaper Thanh Nien in 2020 found foreign academics were being paid to falsely list affiliations with Vietnamese universities to inflate publication counts and rankings — at one point roughly 70% of Ton Duc Thang’s 2022 publications involved external, unaffiliated researchers. A separate 2022 investigation into a large Russian paper mill placed Vietnamese researchers among its top ten purchasers of fabricated authorship slots.

    Tu Van Duong, a senior researcher at Purdue University, described the directive as an “important milestone,” noting that Vietnam’s integrity expectations had previously relied on general principles and voluntary encouragement rather than binding enforcement.

    Common questions on research misconduct penalties

    What are the penalties for research misconduct?

    Penalties typically form a graduated scale: written warnings and retraining for minor lapses, followed by correction or retraction of publications, mandatory supervision, and — for the most serious cases — loss of employment, revoked degrees, permanent funding bans, and in rare cases criminal prosecution for misuse of public funds.

    What are the three types of research misconduct?

    Most frameworks, including the US federal definition and Vietnam’s new guidance, converge on three core categories: fabrication (inventing data or results), falsification (manipulating data, equipment, or processes to misrepresent findings), and plagiarism (using others’ ideas or words without credit).

    What happens if you get caught for academic misconduct?

    An institutional panel investigates the allegation, typically involving academic peers and external members. If misconduct is confirmed, consequences range from a formal reprimand or required correction through to suspension, termination, degree revocation, and referral to funders or professional bodies for further sanction.

    Who investigates allegations of research misconduct?

    Primary responsibility usually sits with the researcher’s own institution, guided by a code of practice such as the UK’s Concordat to Support Research Integrity. National bodies — Vietnam’s Ministry of Science and Technology, the US Office of Research Integrity, Germany’s DFG — provide oversight, funding sanctions, or an appellate role rather than running every case.

    How Vietnam compares: graduated sanctions worldwide

    Vietnam is not acting in isolation. Several jurisdictions have tightened or formalised research misconduct policy in the same window, reflecting a broader shift toward proportionate, publicly verifiable enforcement.

    Jurisdiction / body Mechanism Notable feature
    United States (ORI, NSF) Debarment from federal funding Confirmed cases published publicly
    United Kingdom (UKRI) Funding withdrawal, application bar Institutions face sanction if investigations are inadequate
    Germany (DFG) Exclusion from applying for funds 1–8 year bans, published sanctions list
    Canada (Tri-Agency) Reprimand to lifetime funding ban Comparatively low public transparency
    Scotland (May 2026) New institutional integrity system requirements Sector-wide baseline standard
    Peru (March 2026) Faculty bonus eligibility rules Bars bonuses for researchers with retractions
    India Grant-application disclosure requirement Five-year retraction history must be declared
    Thailand (THRIN) National research integrity network Cross-institutional coordination body
    Vietnam (May 2026) Tiered warnings to indefinite bans Violations logged on a national digital platform

    The common thread is a move away from vague, principle-only guidance toward codified, tiered sanctions with a public or semi-public record — precisely the design pattern uk research misconduct bodies such as UKRIO have long recommended through the Concordat to Support Research Integrity, and that international bodies including the European Network of Research Integrity Offices (ENRIO) are working to harmonise across borders.

    Implications for institutions and research administrators

    For research administrators, Vietnam’s framework is a useful reference point when reviewing a local research misconduct policy. Three implications stand out:

    • Proportionality reduces case backlog. A defined tier structure lets institutions resolve low-severity cases with training or a warning, reserving lengthy formal investigations for fabrication, falsification and plagiarism.
    • Public logging changes deterrence dynamics. A searchable national record — as opposed to institution-only files — raises the reputational stakes of a confirmed finding, mirroring the public debarment lists already run by the US Office of Research Integrity and Germany’s DFG.
    • AI-specific clauses are becoming standard. Explicitly naming fabricated AI outputs and unverified AI citations as misconduct closes a gap that many older policies, including some still in force across UK and EU institutions, have not yet updated to cover.

    Misattributed or inflated authorship — the practice exposed at Ton Duc Thang and Duy Tan — is itself a form of research misconduct, and one that transparent contributorship reporting can help deter. CASRAI originated the CRediT contributor role taxonomy in 2014 to make individual research contributions auditable; the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022. Institutions building or revising misconduct policy alongside authorship criteria and contributor role disclosure requirements give investigators a clearer evidentiary trail when authorship claims are disputed. For teams mapping their own procedures against comparable frameworks, CASRAI’s research administration resources and research integrity terminology reference are a starting point.

    What comes next

    Vietnam’s National Digital Platform will take time to populate, and enforcement consistency across thousands of institutions and provincial science agencies remains untested. The real signal will be whether confirmed cases are actually logged, sanctioned and made visible — the same accountability gap that has historically limited Canada’s Tri-Agency framework and left some European systems reliant on anonymised summaries rather than named findings.

    What is clear is the direction of travel. Alongside Scotland’s new institutional requirements, Peru’s bonus restrictions, and India’s disclosure rules, Vietnam’s tiered penalties add to a growing body of 2026 evidence that funders and governments are converging on graduated, publicly verifiable sanctions rather than one-size-fits-all punishment. For institutions still relying on ad hoc disciplinary procedures, that convergence is now the benchmark to measure against.